MX385788B - Método de tratamiento con tradipitant. - Google Patents

Método de tratamiento con tradipitant.

Info

Publication number
MX385788B
MX385788B MX2017011279A MX2017011279A MX385788B MX 385788 B MX385788 B MX 385788B MX 2017011279 A MX2017011279 A MX 2017011279A MX 2017011279 A MX2017011279 A MX 2017011279A MX 385788 B MX385788 B MX 385788B
Authority
MX
Mexico
Prior art keywords
treatment method
tradipitant
tradipitant treatment
treatment
pruritus
Prior art date
Application number
MX2017011279A
Other languages
English (en)
Spanish (es)
Other versions
MX2017011279A (es
Inventor
Louis William Licamele
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2017011279A publication Critical patent/MX2017011279A/es
Publication of MX385788B publication Critical patent/MX385788B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017011279A 2015-03-04 2016-03-04 Método de tratamiento con tradipitant. MX385788B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US201562232644P 2015-09-25 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Publications (2)

Publication Number Publication Date
MX2017011279A MX2017011279A (es) 2018-01-25
MX385788B true MX385788B (es) 2025-03-18

Family

ID=55629110

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017011279A MX385788B (es) 2015-03-04 2016-03-04 Método de tratamiento con tradipitant.
MX2021010460A MX2021010460A (es) 2015-03-04 2017-09-04 Metodo de tratamiento con tradipitant.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010460A MX2021010460A (es) 2015-03-04 2017-09-04 Metodo de tratamiento con tradipitant.

Country Status (19)

Country Link
US (6) US10463655B2 (enExample)
EP (2) EP3730140A1 (enExample)
JP (4) JP6891385B2 (enExample)
KR (3) KR102860817B1 (enExample)
CN (2) CN113262221A (enExample)
AU (4) AU2016226006B2 (enExample)
BR (1) BR112017018620A2 (enExample)
CA (2) CA2978736C (enExample)
CL (1) CL2017002238A1 (enExample)
DK (1) DK3265087T3 (enExample)
ES (1) ES2824552T3 (enExample)
HR (1) HRP20201627T1 (enExample)
HU (1) HUE050944T2 (enExample)
IL (1) IL254142B (enExample)
MX (2) MX385788B (enExample)
PT (1) PT3265087T (enExample)
RU (1) RU2770050C2 (enExample)
WO (1) WO2016141341A1 (enExample)
ZA (1) ZA201706059B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
HRP20250615T1 (hr) 2017-11-17 2025-07-18 Vanda Pharmaceuticals Inc. Tradipitant za upotrebu u liječenju gastropareze
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021173641A1 (en) 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
JP7791832B2 (ja) * 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
JP2025542424A (ja) 2022-12-21 2025-12-25 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる処置の方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
WO2003091227A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Tachykinin receptor antagonists
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR100848407B1 (ko) 2003-10-24 2008-07-28 일라이 릴리 앤드 캄파니 {2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1h-[1,2,3]트리아졸-4-일]-피리딘-3-일}-(2-클로로페닐)-메탄온의 신규 결정질 형태
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Th1型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
US20090264388A1 (en) 2006-02-22 2009-10-22 Valorisation Recherche Hscm, Limited Partnership Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells
WO2008079600A1 (en) 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
HRP20140759T1 (hr) 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2014093907A1 (en) 2012-12-13 2014-06-19 A.P. Pharma, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
HK1223820A1 (zh) * 2013-06-24 2017-08-11 Menlo Therapeutics Inc. Nk-1受体拮抗剂司洛匹坦在瘙痒中的用途
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
MX378145B (es) 2015-11-30 2025-03-10 Anacor Pharmaceuticals Inc Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
CA3009325A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
HRP20250615T1 (hr) * 2017-11-17 2025-07-18 Vanda Pharmaceuticals Inc. Tradipitant za upotrebu u liječenju gastropareze
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
WO2020117811A1 (en) * 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Also Published As

Publication number Publication date
EP3730140A1 (en) 2020-10-28
HRP20201627T1 (hr) 2021-02-19
US10772880B2 (en) 2020-09-15
CL2017002238A1 (es) 2018-04-20
CN113262221A (zh) 2021-08-17
AU2023233141A1 (en) 2023-10-12
WO2016141341A1 (en) 2016-09-09
US20200360358A1 (en) 2020-11-19
US10463655B2 (en) 2019-11-05
CA3213864C (en) 2026-02-03
US11324735B2 (en) 2022-05-10
AU2016226006B2 (en) 2021-03-04
EP3265087B1 (en) 2020-07-22
CA2978736A1 (en) 2016-09-09
KR20230173743A (ko) 2023-12-27
MX2017011279A (es) 2018-01-25
US20220226295A1 (en) 2022-07-21
MX2021010460A (es) 2021-09-21
BR112017018620A2 (pt) 2018-04-17
RU2017134443A (ru) 2019-04-04
CA2978736C (en) 2023-11-07
AU2023233141B2 (en) 2025-05-22
DK3265087T3 (da) 2020-10-19
HUE050944T2 (hu) 2021-01-28
US20180110761A1 (en) 2018-04-26
ZA201706059B (en) 2023-08-30
IL254142B (en) 2022-05-01
AU2016226006A1 (en) 2017-09-21
EP3265087A1 (en) 2018-01-10
KR102860817B1 (ko) 2025-09-16
RU2770050C2 (ru) 2022-04-14
NZ735121A (en) 2024-07-26
PT3265087T (pt) 2020-10-15
CN107427502A (zh) 2017-12-01
KR20250136946A (ko) 2025-09-16
US20190290625A1 (en) 2019-09-26
JP6891385B2 (ja) 2021-06-18
JP2021073258A (ja) 2021-05-13
CN107427502B (zh) 2021-06-04
AU2025210905A1 (en) 2025-08-21
JP2023052486A (ja) 2023-04-11
US12318375B2 (en) 2025-06-03
ES2824552T3 (es) 2021-05-12
JP2024074963A (ja) 2024-05-31
HK1248552A1 (zh) 2018-10-19
IL254142A0 (en) 2017-10-31
AU2021202956B2 (en) 2023-06-29
AU2021202956A1 (en) 2021-06-03
RU2017134443A3 (enExample) 2019-09-05
CA3213864A1 (en) 2016-09-09
KR20170122777A (ko) 2017-11-06
US20190290626A1 (en) 2019-09-26
JP2018507243A (ja) 2018-03-15
US20250205213A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201691991A1 (ru) Мультиспецифические антитела
MX377710B (es) Anticuerpos monoclonales contra bcma.
EA201792613A1 (ru) Модуляторы cot и способы их применения
MX370807B (es) Anticuerpos que se unen a axl.
PH12017500019A1 (en) Novel ultra-high performance concrete
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
PL3250042T3 (pl) Kompozycja, sposób, zastosowanie i wyrób
BR112016027455A2 (pt) moduladores ppar
EA201792527A1 (ru) Лечение зуда
MX2023009431A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
LT3493849T (lt) N,n-bis-2-merkaptoetilizoftalamido naujas panaudojimas
EP3463579A4 (en) CALLYSPONGIOLID, ANALOGUE FROM IT AND USES THEREOF
EA201792578A1 (ru) Многослойная сборка
RU2014119029A (ru) Способ остеопластической торакопластики из минидоступа
TN2014000384A1 (fr) نظام صوتي ذكي وآمن
TN2014000468A1 (fr) اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها
TN2014000355A1 (fr) طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية
UA114708U (uk) Тяговий привід електробуса
TN2014000377A1 (fr) طائرة كهربائية كاتمة للصوت
TN2014000522A1 (fr) لوح مدرسي بوجهين
UA97245U (en) Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin
TH1601003420A (th) วิธีการผลิตของ 1,3-บิวทาไดอีน